ADVANCES IN SKIN & WOUND CARE • JULY/AUGUST 2004 culation 3, 4 and healing 4 of ischemic wounds. Improved ischemic wound healing was reported in a retrospective study of patients who were treated with HVPC therapy. 4 In the study, 22 patients were evenly divided between the treatment group, which received HVPC plus standard care, and the control group, which received standard care alone. Patients were evenly matched for age, sex, and percentage with diabetes mellitus. The proportion of healed wounds 1 year after starting treatment was higher in the treatment group (90% healed) compared with the control group (30% healed). This difference was significant (P < .05, Fisher exact test). Similarly, mean wound areas were significantly smaller for HVPC-treated wounds from weeks 20 through 52 after the start of treatment (P < .05, Mann-Whitney test). Maximum periwound transcutaneous oxygen (TcPO 2 ) significantly improved for the HVPC group but not for the non-HVPC group compared with pretreatment TcPO 2 (P < .05, Wilcoxon signed rank test). These results suggest that HVPC promotes microcirculation and healing of ischemic wounds. However, the results could not be generalized because they were based on post-hoc analysis of unblinded, nonrandomized clinical data. This suggested a need for a prospective blinded clinical trial.
HVPC consists of direct-coupled continuous trains of pulses, each a submicrosecond doublet of high peak amplitude (> 10 ma). This signal and the electrotherapy device have been sanctioned by the Food and Drug Administration (FDA) through its 510(k) mechanism and have been in use for decades to improve local blood flow.
Although the precise nature of the increased blood flow induced by HVPC is not well understood, it may improve microcirculation. [5] [6] [7] Flow through arterioles in the subdermis and through capillaries in the nutritional and papillary dermis is collectively defined as skin microcirculation. The microcirculation consists histologically of subcutaneous paired arterioles and venules less than 0.1 mm in diameter that perforate muscle and fat layers and a horizontal plexus through the deep dermis. 8 From the horizontal plexus, microvascular units perfuse the superficial dermis, with each unit resembling 3 dimensions of an umbrella arising from a stem. The stem of the umbrella consists of vertical ascending paired arterioles and venules (1.5 to 7 mm apart) that arborize into superficial horizontal plexuses of terminal arterioles and venules within the papillary dermis. Terminal arterioles give rise to capillaries that ascend through dermal papillae, form hairpin curves, and descend into terminal venules within the superficial dermal plexuses. The bulk of the skin microvasculature is contained in the papilary dermis 1 to 2 mm below the surface. The vascular islands, supplied by ascending arterioles, and intervening avascular spaces may form the classical livedo pattern in the presence of proximal ischemia. 8 Microcirculation can be quantified in several ways. TcPO 2 can measure the absolute oxygen partial pressure of the dermis and subdermis, and laser Doppler flow can measure the velocity of red blood cells through the most external 1 mm of dermis, which primarily includes the horizontal papillary plexus and capillary loops. Additional methods of measuring microcirculation include videomicroscopy, 9 which is a direct visualization technique, and skin surface temperature, 10 which is an indirect measure of capillary flow. Although all of these methods are noninvasive, TcPO 2 and laser Doppler flow were selected for this study because of the supporting literature and ease of measurement. 5, [11] [12] [13] [14] [15] [16] [17] [18] [19] TcPO 2 measures absolute partial pressure of oxygen within the entire skin microcirculation and has been termed a blood gas through the skin. Skin and arterial blood gas use a polarographic measurement method. 11 TcPO 2 is a good predictor of wound closure, 12, 13 amputation risk, 14 and healing of a transtibial amputation operative site. 15 A TcPO 2 measurement equalling 20 mm Hg appears to be the threshold below which healing is not favorable; a TcPO 2 measurement greater than 40 is considered favorable for wound healing. For this article, ischemia has been defined as periwound TcPO 2 less than 20 mm Hg. 3, 4 Laser Doppler flow quantifies flow of red blood cells through the upper 1 mm of dermis. Flowmetry measures blood flow change to skin of ischemic musculoskeletal flaps and is used in research models of skin blood flow. 5, [16] [17] [18] Ischemic wounds are painful. 20, 21 Classically, ischemic pain is alleviated by dependency and exacerbated by elevation. Leg elevation occurs with bed rest and explains why ischemic wounds usually hurt more at night. A measure of clinical effectiveness of a treatment for ischemic wounds would reasonably include pain reduction.
A prospective, randomized, single-blinded pilot study of HVPC was conducted for a cohort of outpatients with quasistable ischemic ulcers. HVPC was used to improve healing of ischemic wounds by promoting microcirculation and decrease pain compared with standard care alone.
METHODS
A single-center, single-blinded, balanced, randomized, shamcontrolled clinical trial to determine the feasibility of HVPC to improve microcirculation and healing of infrapopliteal ischemic wounds was performed. The main outcome measure was wound area. Secondary outcome measures were reduced pain and increased perfusion.
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Inclusion and exclusion criteria
Inclusion and exclusion criteria were based on a previous retrospective study. 4 Inclusion criteria were patients with (1) ischemic wounds at or below the knee, including wounds with a black, yellow, or red base; (2) periwound TcPO 2 (or closest available site) less than 20 mm Hg; (3) reasonable motivation to participate in the study; (4) wounds open for at least 4 weeks before inclusion in the study; and (5) arteriosclerotic disease confirmed by a means other than TcPO 2 before inclusion in the study (ie, direct surgical observation, pulse volume recording [PVR], magnetic resonance angiography, or angiogram).
Exclusion criteria were (1) presence of a pacemaker; (2) presence of active or untreated abscess or cellulitis; (3) presence of rapidly extending gangrene or gangrene involving an entire digit; (4) good candidates for arterial bypass, regardless of whether previous bypass had been attempted or completed;
(5) urgent need for amputation; (6) moribund status (extensive, marginally compensated, and worsening multisystem disease); (7) presence of local or systemic process that would prevent accurate periwound TcPO 2 from being determined; and (8) inability to undergo any part of the protocol.
A critical criterion for inclusion was based on the judgment of the team that the wound was quasistable; that is, the wound would not enlarge appreciably over the 14-week study period. Many ischemic wounds have rapidly expanding gangrenous eschar. Wounds that were unstable and otherwise appropriate for HVPC were offered treatment outside the study.
Patients were identified as candidates for the study by the principal investigator and were taken from his patient population or from primary care or specialist referrals. If a patient could benefit by participation, the investigators explained the study to the patient. If the patient was interested, a consent ELECTROTHERAPY PROMOTES HEALING AND MICROCIRCULATION OF INFRAPOPLITEAL ISCHEMIC WOUNDS: A PROSPECTIVE PILOT STUDY *Neuropathy was defined as insensitivity to the Semmes-Weinstein monofilament 39 in 1 of 4 segments: upper leg, midleg, lower leg, or ankle/foot. The ankle/foot segment was involved in all cases for which neuropathy was present. †Initial wound appearance was documented as red = atrophic (rather than granular); yellow = fibrinous eschar; and black = gangrenous eschar Comorbidities: AFIB = atrial fibrillation; CAD = coronary artery disease; CHF = congestive heart failure; CVA = cerebrovascular accident; DM 2 = type 2 diabetes mellitus; ESRD = end-stage renal disease on hemodialysis; HTN = hypertension; S/P CABG = status postcoronary artery bypass graft 
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form was provided and a formal screening visit was scheduled. At the screening visit, investigators conducted a cognitive test to ensure that the patient understood the protocol and consent form. If so, the patient signed the consent form. Thereafter, the investigator conducted a screening interview, including a detailed history and physical examination; TcPO 2 was measured if it had not been done in the previous 3 weeks. If a subject met all entry criteria, a week 0 visit was scheduled.
Randomization
At week 0, the investigators unsealed sequentially numbered envelopes to determine subject assignment for every other subject (HVPC or control). The next subject was assigned to the treatment not listed in the envelope. This pair-wise method ensured equal assignment of subjects between the 2 groups. The blinding was not disclosed to the subjects until week 14. A serious device-related adverse event also would have prompted disclosure of the blinding; however, none occurred. Study personnel were unblinded to subject assignment.
Study protocol
Based on random assignment, subjects were either provided an active HVPC unit or a sham HVPC unit. Subjects of both groups were told they may or may not feel the tingle of electrotherapy. Active HVPC or sham HVPC was applied at home 1 hour per day, 7 days per week, for 14 weeks.
For the 14-week observation period, complete assessments occurred on weeks 0, 4, 8, 12, and 14; all assessments were ±1 week. At each assessment, the investigators measured (1) wound area by digital planimetry, (2) wound appearance by serial photography, (3) TcPO 2 , (4) laser Doppler flow, (5) pain by a visual analogue method, and (6) adverse events. A baseline PVR study obtained within 2 months of study entry was available for 6 of 8 subjects.
Protocol modifications were approved by the University of Pennsylvania Institutional Review Board. The first 2 subjects enrolled were unblinded, and the control subject of this pair did not receive a sham HVPC unit. After these 2 subjects completed the study, the protocol was revised to its present form (single-blinded and sham-controlled) for the remaining subjects (n = 6). To increase recruitment, for the last year of the protocol the initial inclusion criteria of wounds at or below the ankle was changed to those at the knee or below.
Wound measurement
Wound area was determined by digital planimetry employing a method previously described in detail. 3, 11 Briefly, the wound outline is traced on clear plastic with a marking pen; wound area is determined by a computer. Digital planimetry has excellent reported intrarater and interrater reliability and concurrent validity compared with other objective methods of determining wound area. 3, 22 If a subject had more than 1 wound on or below the ankle, the index wound was the one for which periwound TcPO 2 was less than 20 mm Hg. If the index wound became 2 wounds as it healed, both wound areas were measured and summed to find the wound area. Wound appearance was documented with a Nikon CoolPix 990 digital camera (Nikon, Melville, NY).
TcPO 2
For TcPO 2 monitoring, 3 or 4 Novametrix 840 or 860 systems were used (Novametrix Medical Systems, Inc, Wallingford, CT). This method has been previously described in detail. 3, 11 Three calibrated electrodes were affixed to each subject's skin. One electrode was placed on the periwound skin or as close as possible to the ischemic area; the second was placed within 10 cm of the wound on nearby skin (ie, on the plantar arch or dorsum of the foot); and the third electrode was placed on a fartherremoved, well-perfused area (ie, the upper leg). If 2 or 3 electrodes were the same distance from the wound, both values were averaged. Once sites were assigned and baseline values established for a given subject, sites were not changed over successive TcPO 2 determinations.
Laser Doppler flow
Flow of erythrocytes within the most superficial 1 mm of viable dermis was assessed for this study using a Perimed PF4001 laser Doppler flowmeter (Perimed AB, Järfälla, Sweden). The flowmeter had 2 channels, and 2 miniature fiber optic probes. Each probe was secured on the periwound skin at opposite poles of an ischemic wound. Sites were not changed over successive laser Doppler measurements. Skin blood flow was reported in laser Doppler units (LDU), and LDU values on the display were recorded at the time of the final TcPO 2 determination. The values from both probes were averaged and reported as periwound laser Doppler flow. Vasomotion 8 was not recorded.
Pain measurement
At every visit, the patient was asked to quantify his or her pain on a 10-cm line, without viewing previous responses. The distance was recorded on an interval scale.
Electrotherapy
Electrotherapy parameters and techniques have been previously described in detail. 3, 11 A Home Therapy Products (UTS, Inc, Tampa, FL) or Intelect HVP (Chattanooga Group, Hixson, TN) system supplied home-based HVPC for treatments of approximately 1 hour daily for 14 weeks. Stimulation parameters were set at negative polarity, 100 pulses per second, and amplitude was increased until sensory threshold or the maximum of 360 volts was reached. Negative polarity was maintained for the active electrodes. A data-logging feature, available on the Home Therapy Products or Intelect units, stamped the time, date, and duration of treatment.
Sham HVPC units (Micro-Z; Prizm Medical, Duluth GA) were custom-modified to produce no active signal and were identical to sham units employed for another wound healing clinical trial. 23 Physically, they were smaller in size than the Home Therapy Products or Intellect units, but had controls and lights that behaved in a convincing fashion. In addition, the Micro-Z units had built-in software to monitor usage.
Electrode placement and electrotherapy techniques were identical for active HVPC and sham HVPC units.
After assessment at week 0, electrotherapy was applied at home 1 hour per day, 7 days per week. One subject in the control group used the Prizm device for 4 weeks during a stay at a skilled care facility and was supervised by a physical therapist prior to being discharged home. Each unit was connected to 2 active electrodes and 1 return electrode. All electrodes were made of commercially available carbon rubber material. The large return electrode was positioned on the ipsilateral thigh or leg of the treated foot. Active electrodes were placed directly over the ischemic lesion, which was protected from the electrode by a conductive hydrogel layer (VIGILON Primary Wound Dressing; Bard Medical Division, CR Bard, Inc, Covington, GA).
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Standard wound care
All subjects received conventional wound care, including (1) protection of ischemic skin lesions from mechanical trauma using padding and from excessive pressure and shear using padding and protection (eg, ABD pads, Kerlix, and DH Walker); (2) silver sulfadiazine ointment applied to black or yellow eschar to reduce bacterial count 24 ; (3) antibiotic ointment or hydrogel applied to the granulating wound base to maintain a moist wound environment; (4) gait training with an assistive device for protected weight bearing; (5) frequent debridement of nonischemic wounds 25 ; and (6) frequent wound inspection by a visiting nurse. The visiting nurse is the basis of at-home wound care, and, in many studies, close supervision by a visiting nurse improves the rate of limb salvage as much as 40%. 26 The protocol and consent form were approved by the University of Pennsylvania Institutional Review Board. The protocol was implemented in compliance with good clinical practice guidelines. 27
Statistical tests
The Student t test was used to determine statistically significant differences between primary and secondary outcome variables for a given week.
RESULTS
During a 2 1 ⁄ 2-year period, 8 subjects met the entry criteria and were willing to participate in the study. Four subjects were randomized to each group. No significant differences were found between the subjects enrolled in the HVPC and control groups for age (78 ± 11 years and 65 ± 20 years, respectively) or male to female ratio (1:3 and 3:1, respectively; Tables 1 and 2) . Comorbidities appeared to be distributed similarly between the subjects in the HVPC and control groups, with respect to type 2 diabetes mellitus (n = 2 and n = 1, respectively) and endstage renal disease on hemodialysis (n = 1 in each group). Three subjects in each group previously underwent vascular bypass grafting or angioplasty ipsilateral to the index wound. Of these revascularization procedures, 2 in the HVPC group and 1 in the control group had ceased to effectively function by the time of study enrollment.
Wound characteristics
At week 0, no differences were detected in wound size of subjects in the HVPC and control groups (10.0 ± 6.6 cm 2 and 7.7 ± 10.0 cm 2 , respectively) and duration of the wound (6.3 ± 4.0 months and 7.0 ± 4.2 months, respectively) ( Table 2 ). Wounds were variable in initial appearance: atrophic red (HVPC group, n = 1; control group, n = 2), yellow (HVPC group, n = 2; con-trol group, n = 1), or black (each group n = 1). Two subjects in the HVPC group and 1 subject in the control group had postsurgical wounds. The remaining wounds were due to mixed etiologies: venous insufficiency (HVPC group, n = 2; control group, n = 1) or minor trauma (control group, n = 2).
Cumulative healing rate
Initially, the wound area in subjects in the control group increased 50% during the first 4 weeks, mirroring a general tendency of ischemic wounds to increase in size 3, 4 (Figure 1 ). Wounds treated with HVPC decreased in size during the same period, leading to a significant difference in wound area after 4 weeks (P < .05, Student t test; n = 4 each group). After 4 weeks, HVPC-treated wounds continued to steadily decrease in area. Although wound area initially expanded in the control group, a positive healing rate was eventually seen. However, the healing rate in the control group continued to lag behind the healing rate for HVPC-treated wounds during the 14week period.
TcPO 2
At week 0, the mean TcPO 2 for both groups showed critical ischemia (less than 10 mm Hg; Figure 2 ); however, wounds in the HVPC group tended to have a higher periwound mean TcPO 2 than wounds in the control group (6.5 ± 9.8 mm Hg vs 0 ± 0 mm Hg, respectively). This discrepancy was due to 1 subject in the HVPC group who had an ischemic wound on screening evaluation (TcPO 2 = 11 mm Hg) that became borderline ischemic on week 0 (TcPO 2 = 21 mm Hg) and ischemic on week 4 (TcPO 2 = 12 mm Hg). By week 8, HVPC-treated wounds as a group tended to rise out of the ischemic range; control wounds did not (27 ± 12 mm Hg vs 2 ± 2 mm Hg; P < .05, Student t test). Wounds in the control group showed signs of reoxygenation by week 12, averaging a mean of 15 mm Hg on weeks 12 and 14. On week 14, HVPC-treated wounds averaged 30 mm Hg, well out of the ischemic range.
Laser Doppler
Dermal capillary perfusion measured by laser Doppler flow increased for wounds in the HVPC group compared with the control group. Initially and at week 4, no differences were found in dermal capillary perfusion ( Figure 3) ; however, on week 8, HVPC-treated wounds showed a 3-fold significant increase in dermal periwound perfusion (P < .01, Student t test; control group, n = 4; HVPC group, n = 3) that persisted at week 12 (P < .05, Student t test; control group, n = 4; HVPC group, n = 3).
Pain measurement
Continuous visual analogue scale measurements for wounds in the HVPC and control groups reflected that pain decreased for both groups during the course of the study. If subjects with distal peripheral neuropathy were excluded from the analysis (HVPC group, n = 2; control group, n = 3), pain improvement for wounds in the HVPC and control groups were similar (HPVC group, week 0 pain = 4.7 ± 0.3, week 14 pain = 2.4 ± 2.9, delta = 2.3; control group, week 0 pain = 6.5 ± 3.1, week 14 pain = 4.4 ± 0.7, delta = 2.1).
Adherence to therapy
All subjects verbally reported that they used an active HVPC or sham HVPC device for 1 hour per day, 7 days per week. To confirm treatment history, the active HVPC devices had a datalogging feature with a date and time stamp. This feature was used to periodically check adherence to therapy. Adherence was confirmed in terms of sessions per week (range, 6 to 7 days) and hours per session (60 to 67 minutes). The data-logging feature monitored activity for 3 of 4 subjects in the HVPC group. Monitored data were available for 3 weeks for 2 subjects and for 8 weeks for 1 subject. The fourth subject who received an active HVPC device was confirmed to be adhering to therapy by means of a daily logbook.
Adverse events
Three serious adverse events occurred during the 14-week trial; as previously stated, it is unlikely that any were related to use of the device. Two subjects experienced loss of hemodialysis access requiring brief hospitalization, after which the subjects resumed the study protocol. One of these subjects (patient Tx-2) subsequently developed systemic calciphylaxis requiring hospitalization and discharge from the study at week 7. One week later, the patient died.
One nonserious adverse event was associated with the ELECTROTHERAPY PROMOTES HEALING AND MICROCIRCULATION OF INFRAPOPLITEAL ISCHEMIC WOUNDS: A PROSPECTIVE PILOT STUDY device: In 1 subject, a rash occurred around the large dispersive electrode; it resolved after applying hydrocortisone 2.5% ointment to the affected area for 1 to 2 weeks.
DISCUSSION
HVPC electrotherapy appeared to have an immediate positive influence on healing and perfusion of ischemic wounds in the present study. The area of HVPC-treated wounds steadily decreased with time. Wounds in the control group initially increased in area, then improved on average. As the mean area of the wounds in the control group improved, variability tended to increase with time. This variability was also noted for a retrospective observational study of HVPC effect on ischemic wounds 4 and reflects the heterogenous nature of ischemic wound outcomes: Some eventually heal, some worsen. The rapid decrease in wound area of HVPC-treated wounds may be partially due to improvement in periwound microcirculation. Although the authors have previously noted improvement in TcPO 2 associated with HVPC application, 3, 4 this is the first confirmation of improvement in microcirculation by 2 tests that measure different physiologic processes, namely periwound oxygenation measured by TcPO 2 and dermal capillary perfusion of subdermal arterioles measured by laser Doppler flow.
It was expected that ischemic wounds would remain ischemic. Although this was true on average, TcPO 2 of wounds tended to improve by week 14 for subjects in the control group. This may have been due to several factors: (1) consistent attention to reducing repetitive trauma with liberal padding over the primary dressing, (2) appropriate application of orthotics, including the DH Walker 23 ; and/or (3) assistive devices for partial weight bearing and gait training. 28 In addition to appropriate pathomechanic management, a moist wound environment was maintained as the treatment of choice. As a result of conservative healing strategies, 3 of 4 wounds in the control group showed signs of healing by week 14.
The control group represented a subset of ischemic wounds that were stable (not rapidly expanding) and were therefore likely to eventually heal with sufficient time and care. However, standard wound care alone cannot resolve critically ischemic cutaneous gangrene. The natural history of gangrenous wounds is to expand. Rapidly expanding wounds were excluded from this protocol due to ethical considerations, including risk of limb loss. If rapidly growing wounds were to be included in a prospective trial, the results could mirror those of Goldman et al. 4 In that study, critically ischemic wounds that were expanding rapidly in area responded dramatically to HVPC, 4 with a significant improvement in proportion healed 1 year after the start of observation.
By reversing wound expansion, HVPC may speculatively reduce the risk of skin graft failure, musculocutaneous graft failure, or osteomyelitis. However, limb salvage is more difficult to predict because most subjects in the control group elected to receive HVPC for at least 3 additional months after the 14week experimental period. Nevertheless, 1 subject in the control group had an amputation at the 1-year follow-up mark; no amputations occurred in the HVPC group. The ideal primary endpoint for a wound healing clinical trial is complete wound closure. 29 In the authors' opinion, however, wound closure is a potentially unsafe endpoint for ischemic wounds due to their tendency to expand in area. This tendency suggests the advisability of a time-limited period, during which healing behavior is observed. Even with a time-limited experimental period, many referring clinicians expressed concern about wound destabilization and tissue loss, leading to careful selection of subjects for this study.
Because of the small sample size of the groups in this prospective series, caution must be used in generalizing these results to the larger population of ischemic wounds. Even with randomization, an outlier in either group could skew the results and lead to type 1 error. (Type 1 error rejects the null hypothesis when it is true.) For this reason, a larger Phase II trial is required to confirm these findings. A future study is planned that will be structured according to a power analysis based on the null hypothesis that no differences exist between HVPC and control means, with the alternate hypothesis being that the true difference between means equals 0.4814 (combining area data from weeks 4, 8, 12, and 14) . The estimates of within-subject time variance and covariance are obtained by fitting a repeated measures model, including effects for treatment, week, and treatment-week interaction. In order to reject the null hypothesis at 80% power, a sample size of 12 subjects per treatment group (24 overall) is needed; to reject it at 90% power, 15 subjects per group (30 overall) are needed for a Phase II study.
The authors speculate that HVPC reverses wound area expansion and increases microcirculation by release of nitric oxide (NO) in the microenvironment. Nitric oxide is a vasodilator and protects ischemic tissue from reperfusion injury. 30 In wound models, electric signals similar to HVPC induce action potentials to flow antidromically toward distal terminals of sensory afferent nerve fibers. These terminals then release the polypeptide substance P and/or vasoactive intestinal polypeptide (VIP). These vasoactive polypeptides induce endothelial cells to release NO, which then dilates dermal and subdermal arterioles and precapillaries. Consistent increases in NO concentration have been measured peripherally in the rat hind paw in response to HVPC-like stimulation of the sciatic nerve. 31 A mechanism whereby sensory afferents mediate the ELECTROTHERAPY PROMOTES HEALING AND MICROCIRCULATION OF INFRAPOPLITEAL ISCHEMIC WOUNDS: A PROSPECTIVE PILOT STUDY response of HVPC does not explain how patients with peripheral neuropathy respond with healing and an increase in microcirculation-a phenomenon noted in this and a previous study. 4 To offer a possible explanation, mast cells may independently mediate a response to HVPC. HVPC-like stimulation of porcine skin reduces apparent mast cell concentration, 32 which may represent mast cell degranulation. 33 Degranulation of mast cells releases cytokines, growth factors, and NO, which may orchestrate vasodilation, fibroplasia, and neovascularization. 34 Increased structural density of microvessels may also accompany HVPC treatment in the longer term. At 8 to 12 weeks of treatment, HVPC is associated with an increase in periwound blood flow in the superficial dermis. Capillary and terminal vessel proliferation is promoted by vascular endothelial growth factor (VEGF) in ischemic tissue. 35 VEGF-induced capillary formation is facilitated by NO; NO then potentiates keratinocytes to produce more VEGF in response to keratinocyte growth factor-2 (KGF-2), interleukin-1 (IL-1), tumor necrosis factor α (TNF-α), and transforming growth factor-β (TGF-β), 36 which are ubiquitous in chronic healing wounds. Ischemic wounds often occur in patients with diabetes.VEGF production has been found to be deficient in animal models of diabetes. 37 Additionally, glycosylated proteins caused by hyperglycemia sequester NO. 38 Nitric oxide speculatively released by HVPC may reverse such deficits.
CONCLUSION
In a prospective, randomized, single-blinded sham-controlled clinical trial of ischemic wounds treated with HVPC electrotherapy, HVPC-treated wounds decreased in size, reversing the expected increase in ischemic wound size observed for wounds in the control group (P < .05, week 4). A trend toward smaller wound area continued for the 14-week trial period for wounds in the HVPC group compared with the control group. Improvement was consistently seen in periwound microcirculation measured by TcPO 2 and laser Doppler at week 8 and laser Doppler at week 12. These results suggest that HVPC promotes arteriolar vasodilatation and dermal capillary formation. HVPC was well tolerated.
The promising results of this pilot study require a larger Phase II study to confirm and generalize findings. In the long run, HVPC, or a similar active signal, could serve as a relatively safe and effective complement to surgical revascularization to improve the odds of healing ischemic wounds, reducing complications, and promoting limb salvage. •
